27.09.2011 • News

AmerisourceBergen To Buy Theracom For $250 Million

Pharmaceutical services company AmerisourceBergen announced the signing of a definitive agreement to purchase Theracom a subsidiary of CVS Caremark for $250 million. The acquisition is expected to be neutral to fiscal year 2012 earnings, and slightly accretive in fiscal 2013.

Theracom, with an annualized revenues of around $700 million, provides a wide range of support to pharmaceutical and biotechnology drug manufacturers including consulting and reimbursement services and deal will be closed in the first quarter, ending December 31. The combination is expected to expand AmerisourceBergen's reimbursement, adherence and patient access services for pharmaceutical and biotech.

Theracom will join Lash Group as part of AmerisourceBergen Consulting Services. Lash Group and Theracom will offer an extensive platform of services and solutions to support the growing demand for patient access and reimbursement services, and support the need for unique distribution solutions.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.